Skip to content

Evaluating Khadira and Shigru Capsule for High Cholesterol Management

A ANALYTICAL RANDOMISED COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF KHADIRA TWAK CAPSULE AND SHIGRU TWAK CAPSULE IN THE MANAGEMENT OF MEDOROGA W.S.R.TO HYPERLIPOPROTEINEMIA - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110463
Enrollment
60
Registered
2026-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E784- Other hyperlipidemia

Interventions

None listed

Sponsors

MADAN MOHAN MALVIYA GOVERNMENT AYURVED COLLEGE UDAIPUR RAJASTHAN
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1,Patients willing to participate and follow the scheduled Visit plan, instruction, laboratory test present clinical trial with consent. 2.The patients, whom age between 18-70 years old. 3. Patients with previously diagnosed and confirmed known patient of Hyperlipoproteinemia. 4.Confirmed diagnosis of Hyperlipoproteinemia based on lipid profile tests (elevated total cholesterol range between 239 to 400 mgldl or LDL-C range between 159 to 400 mg/dl or triglycerides ranige between 199 to 700 mg/dl or low HDL-C from baseline value). 5. Patients having Peptic ulcers or any other bleeding disorders for Khadir Ghana capsule.

Exclusion criteria

Exclusion criteria: 1.The patient who used other anti-hyperlipidemic drugs four weeks before enrollment. 2. Patients of uncontrolled endocrine or metabolic disorder. 3. Patients who are taking oral steroids. 4. Patients having major illness malignancy, renal insutticiency etc. 5. Alcohol consumers and drug abusers. 6. Pregnant and lactating women. 7. Patients having Peptic ulcers or any other bleeding disorders for shigru Ghana capsule.

Design outcomes

Primary

MeasureTime frame
1. Reduction in lipid levels and improvement in lipid profiles. 2. Acacia catechu & Moringa oliferia are safe and well tolerated in patients with Hyperlipoproteinemia.Timepoint: 2 month

Secondary

MeasureTime frame
1. Improve the quality of life and overall wellbeing in patients with Hyperlipoproteinemia. 2. I will identify potential adverse effects or interaction with other medications. 3. Reduction in LDC-C levelTimepoint: 30 days,60 days,90 days

Countries

India

Contacts

Public ContactDR AISHWARYA CHOUDHARY

MADAN MOHAN MALVIYA GOVERNMENT AYURVED COLLEGE

drkaushal2002@yahoo.com9983557708

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026